Riverside, California 92506

  • Alzheimer Disease

Purpose:

This is a 15-month study with two phases. During the first 12-month phase of this study, patients will be randomly assigned to receive either active study drug or placebo (approximately half of all patients will be on active study drug, the other half on placebo). The second phase is a 3-month randomized withdrawal period. For this phase approximately 10% of the patients will remain on the active drug.


Study summary:

This is a placebo-controlled, parallel-groups, 12 month, double-blind study, followed by a 3-month, double-blind, randomized withdrawal period to evaluate the efficacy and safety of an investigational drug (currently approved for other indications) to slow the progression of symptoms of AD. Patients with probable AD according to NINCDS-ADRDA criteria who have a Mini Mental State Examination (MMSE) score between 13 and 26 inclusive will be eligible for participation in the study. Patients on stable doses of marketed cholinesterase inhibitors approved for the treatment of AD (except for tacrine) for at least 3 months are eligible for study entry. Use of NSAIDs (except aspirin 81 mg per day) is not allowed during the study.


Criteria:

Inclusion Criteria: - Patient is male or female and at least 50 years of age or older - Female patients must be postmenopausal or surgically sterilized - Clinical diagnosis of AD - Patient must be in good health except for AD diagnosis - Patient must have informant/caregiver who can monitor and assist patient during the study Exclusion Criteria: - Patient is living in a nursing home or skilled nursing facility - Women will be ineligible if not postmenopausal or surgically sterilized - Site physician or Sponsor may exclude patients with serious medical problems such as cancer, cardiovascular disease, major neurological or psychiatric illness, thyroid disease, or major head trauma


Study is Available At:


Original ID:

IA0025


NCT ID:

NCT00006187


Secondary ID:


Study Acronym:


Brief Title:

The Safety and Efficacy of an Investigational Drug in Delaying the Progression of Alzheimer's Disease


Official Title:


Overall Status:

Terminated


Study Phase:

Phase 3


Genders:

Both


Minimum Age:

50 Years


Maximum Age:

N/A


Quick Facts

Healthy Volunteers
Oversight Has DMC
Study Is FDA Regulated
Study Is Section 801
Has Expanded Access

Study Source:

National Institute on Aging (NIA)


Oversight Authority:

Unspecified


Reasons Why Stopped:


Study Type:

Interventional


Study Design:

Allocation: Randomized, Endpoint Classification:


Number of Arms:

0


Number of Groups:

0


Total Enrollment:

0


Enrollment Type:


Overall Contact Information

Official Name:Klaus Beck, MD, PhD
Principal Investigator
Merck

Study Dates

Completion Date:June 2005
Completion Type:Anticipated
Primary Completion Date:June 2005
Primary Completion Type:Anticipated
Verification Date:October 2003
Last Changed Date:December 10, 2009
First Received Date:August 25, 2000

Study Outcomes

There are no available Study Outcomes

Study Interventions

Intervention Type:Drug
Name:Investigational drug

Study Arms

There are no available Study Arms

Study Agencies

Agency Class:Industry
Agency Type:Lead Sponsor
Agency Name:Merck

Sample and Retention Information

There are no available Sample and Retention Information

Study References

There are no available Study References

Data Source: ClinicalTrials.gov

Date Processed: April 03, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


This study is not currently recruiting Study Participants. The form below is not enabled.